Literature DB >> 15618754

CYP2D in the brain.

Yoshihiko Funae1, Wataru Kishimoto, Toshio Cho, Toshiro Niwa, Toyoko Hiroi.   

Abstract

CYP2D1, 2D2, 2D3, and 2D4 are major CYP2D isoforms expressed in the rat. In humans, only CYP2D6 is expressed. In rat brain, the mRNA for CYP2D4 is most abundant in cerebellum, striatum, pons and medulla oblongata. In human brain, CYP2D6 mRNA expression was detected in all regions with highest levels observed in cerebellum. CYP2D isoforms are involved in the metabolism of not only xenobiotics such as antidepressants, beta-adrenergic blockers, antiarrhysthmics, and antihypertensives, but also endogenous compounds such as trace amine and neurosteroids. Among 11 isoforms of human recombinant P450s, only CYP2D6 exhibited an ability to efficiently convert tyramine which exists in the brain, to dopamine. CYP2D4 and CYP2D6 which are the predominant CYP2D isoforms in the rat and human brain, respectively, possess 21-hydroxylation activity for both progesterone and allopregnanolone. CYP2D4, not P450c21, works as a steroid 21-hydroxylase in the brain. These results suggested that CYP2D in the brain may be involved in the metabolism of neuronal amines and steroids and in the regulation of the central nervous system.

Entities:  

Year:  2003        PMID: 15618754     DOI: 10.2133/dmpk.18.337

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  10 in total

1.  Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.

Authors:  Chitra Sridar; Natasha T Snider; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-02-02       Impact factor: 3.922

2.  Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys.

Authors:  R T Miller; S Miksys; E Hoffmann; R F Tyndale
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 3.  Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.

Authors:  Natasha T Snider; Vyvyca J Walker; Paul F Hollenberg
Journal:  Pharmacol Rev       Date:  2010-02-04       Impact factor: 25.468

4.  Effect of Human Cytochrome P450 2D6 Polymorphism on Progesterone Hydroxylation.

Authors:  Toshiro Niwa; Shoko Sasaki; Yuka Yamamoto; Mayu Tanaka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-15       Impact factor: 2.569

5.  A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.

Authors:  Natasha T Snider; James A Nast; Laura A Tesmer; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-01-26       Impact factor: 4.436

6.  Cytochrome P450 oxidoreductase participates in nitric oxide consumption by rat brain.

Authors:  Catherine N Hall; Robert G Keynes; John Garthwaite
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

7.  In situ hybridization study of CYP2D mRNA in the common marmoset brain.

Authors:  Yoshinori Shimamoto; Kimie Niimi; Hiroshi Kitamura; Sae Tsubakishita; Eiki Takahashi
Journal:  Exp Anim       Date:  2016-06-29

8.  Influence of cytochrome P450 2D6 polymorphism on hippocampal white matter and treatment response in schizophrenia.

Authors:  Wonsuk Shin; Minji Bang; Anhye Kim; Doo-Yeoun Cho; Sang-Hyuk Lee
Journal:  NPJ Schizophr       Date:  2021-01-29

Review 9.  A Review of the Important Role of CYP2D6 in Pharmacogenomics.

Authors:  Christopher Taylor; Ian Crosby; Vincent Yip; Peter Maguire; Munir Pirmohamed; Richard M Turner
Journal:  Genes (Basel)       Date:  2020-10-30       Impact factor: 4.096

10.  Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms.

Authors:  Przemysław J Danek; Władysława A Daniel
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.